LOX is highly expressed in patients with gastric cancer, indicating poor prognosis and possibly promoting the progression of cancer cells through ECM receptor I interaction and TGF-β, Wnt, JAK–STAT, and mTOR signaling pathways [37, 38]. This evidence concerns the gene LOX and gastric cancer.